TY - JOUR T1 - On Topological Properties of COVID-19: Predicting and Controling Pandemic Risk with Network Statistics JF - medRxiv DO - 10.1101/2020.09.17.20197020 SP - 2020.09.17.20197020 AU - Mike K.P. So AU - Amanda M.Y. Chu AU - Agnes Tiwari AU - Jacky N.L. Chan Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/18/2020.09.17.20197020.abstract N2 - The spread of coronavirus disease 2019 (COVID-19) has caused more than 24 million confirmed infected cases and more than 800,000 people died as of 28 August 2020. While it is essential to quantify risk and characterize transmission dynamics in closed populations using Susceptible-Infection-Recovered modeling, the investigation of the effect from worldwide pandemic cannot be neglected. This study proposes a network analysis to assess global pandemic risk by linking 164 countries in pandemic networks, where links between countries were specified by the level of ‘co-movement’ of newly confirmed COVID-19 cases. More countries showing increase in the COVID-19 cases simultaneously will signal the pandemic prevalent over the world. The network density, clustering coefficients, and assortativity in the pandemic networks provide early warning signals of the pandemic in late February 2020. We propose a preparedness pandemic risk score for prediction and a severity risk score for pandemic control. The preparedness risk score contributed by countries in Asia is between 25% to 50% most of the time after February and America contributes close to 50% recently. The high preparedness risk contribution implies the importance of travel restrictions between those countries. The severity risk score of America is greater than 50% after May and even exceeds 75% in July, signifying that the control of COVID-19 is still worrying in America. We can keep track of the pandemic situation in each country using an online dashboard to update the pandemic risk scores and contributions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work described in this paper was partially supported by a grant from the Research Grants Council of the Hong Kong Special Administrative Region, China (16307217).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N.A.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available in in http://covid-19-dev.github.io/. ER -